Eucrates Biomedical Acquisition in a regulatory filing said shareholders yesterday approved a deadline extension until April 27, 2023. The SPAC’s termination date would otherwise have been tomorrow.
Shareholders redeemed 9,253,065 ordinary shares, representing 88% of the stock sold in the SPAC’s October 2020 IPO. About $12.4 million remains in the Eucrates trust. Read more.
